Ind-Swift Laboratories Limited
INDSWFTLAB · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹137.7. Low-confidence estimate — limited data.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%3.2%
- ✓Low debt (D/E < 0.5)0.01x
- ✕Positive free cash flow
- ✕Revenue growth > 10%-67%
- ✕Earnings growing-95%
- ✕Net margin ≥ 10%6.5%
- ✓Current ratio > 1.53.80
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 3.61
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-16Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Shareholding
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Trading near its 52-week high.
- •Financially solid — Altman Z 3.61.
Weaknesses
- •Low return on equity (3.2%).
- •Weak Piotroski score (2/9).
Opportunities
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hyperparathyrodism, analgesic, aromatase inhibitor, nootropic, antidiarrhoeal/antip
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.